JPMorgan on ORIC Pharmaceuticals (ORIC): 'We Are Buyers On Weakness'
Tweet Send to a Friend
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $21.00 price target on ORIC Pharmaceuticals (NASDAQ: ORIC).The analyst comments "Net-net ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


